Medication-related osteonecrosis of the jaw (MRONJ) has been associated with use different drugs administered in treatment malignant neoplasms or metastases and antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism action is to prevent activation RANK receptor on surface osteoclasts, jaw. Primary intraosseous squamous cell carcinoma (PIOSCC) rare neoplasm charac...

Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first onstudy skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression or survival (Stopeck et al. JCO 2010, Fizazi et al. Lancet 2011). Many SREs were silent compression fractures found only because of scheduled imagin...

de Beus et al. report a case of a patient with immobilization-related hypercalcaemia and advanced renal insufficiency that did not respond to bisphosphonates, and after a single dose of denosumab (60 mg), a rapid and sustained decrease of the serum calcium concentration was observed with a transient hypocalcaemia which needed the introduction of oral calcium and active vitamin D to correct it [...

BACKGROUND Bone metastases are common in patients with hormone-refractory prostate cancer. In a study of autopsies of patients with prostate cancer, 65%-75% had bone metastases. Bone metastases place a substantial economic burden on payers with estimated total annual costs of $1.9 billion in the United States. Skeletal-related events (SREs), including pathologic fractures, spinal cord compressi...

Introduction: Denosumab is indicated in oncology to reduce tumoral development. However, this medication may cause osteonecrosis of the jaw, especially after dental extractions. Drug holiday has been proposed decrease risk jaw. This survey aimed assess management drug holidays for patients who needed both extraction and denosumab. Methods: A questionnaire was sent a panel healthcare professiona...

Torregrosa reports a rare case of dramatic increase in intact parathyroid hormone (iPTH) and hypocalcaemia after administration of denosumab in a kidney-transplanted patient [1]. However, the author does not comment on another important finding of this case which is the unusually prolonged hypocalcaemia. In the only study to have investigated this issue so far, Block et al. report that in the c...

The aim of drug treatment of osteoporosis is the balance between activity of osteoblasts and osteoclasts with aug- mentation of mineral bone density and decrease of fracture risk. Antiresorptive agents depress osteoclasts and diminish resorption of bone. They include bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, while hormone replacement therapy and calcitonin are ...

• Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increase in bone fragility and the risk of fractures. • In Bulgaria, denosumab 60mg subcutaneous is prescribed for the treatment of postmenopausal osteoporosis (PMO) by specialists (endocrinologists and rheumatologists) and reimbursed for patients with a T-score ≤ -2.5 at one or m...

Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemot...